Grant: Project Grant
University of British Columbia
$524,026.00
Non-contact screening technology to expedite cell line development for antibody production
FY 2019-20
Summary
Antibodies are naturally produced by the body's immune cells as defense against infection. These molecules, produced by an external source, could also be used as medicine to treat a wide range of diseases, including cancer, multiple sclerosis, and rheumatoid arthritis. A key barrier in developing antibody-based medicines is producing sufficient quantities of these molecules for various stages of rigorous testing. Antibodies are typically manufactured using producer cells that are grown in the laboratory. This project will develop a technology to develop better producer cells in order to increase their productivity. This capability will dramatically reduce the timelines required to develop antibody-based medicines, resulting in faster and more cost-effective medicines for patients.
Department
Program
Project Grant
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
408245
Name
Ma Hongshen
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Commercialization
Projecttitle
Non-contact screening technology to expedite cell line development for antibody production
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$524,026
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Antibody; Biologics; Bioproduction; Cell Line Development; Drug Development; Screening
Abstract
Antibodies are naturally produced by the body's immune cells as defense against infection. These molecules, produced by an external source, could also be used as medicine to treat a wide range of diseases, including cancer, multiple sclerosis, and rheumatoid arthritis. A key barrier in developing antibody-based medicines is producing sufficient quantities of these molecules for various stages of rigorous testing. Antibodies are typically manufactured using producer cells that are grown in the laboratory. This project will develop a technology to develop better producer cells in order to increase their productivity. This capability will dramatically reduce the timelines required to develop antibody-based medicines, resulting in faster and more cost-effective medicines for patients.
Competitiondate
201909
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ma, Hongshen
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $524,026~ $0~